Insys Therapeutics says investigational epinephrine nasal spray shows 'promise'
INSYS Therapeutics announced that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. In a pharmacokinetics study involving 60 people with seasonal allergies, preliminary results showed that the bioavailability of the company's novel, proprietary formulation of epinephrine delivered intranasally was similar to that of intramuscular injection with EpiPen. The study also demonstrated rapid drug absorption with the epinephrine nasal spray. According to the Mayo Clinic, more than 200,000 cases of anaphylaxis occur each year in the United States. The World Allergy Organization estimates that up to two percent of the global population-as many as 150M people worldwide-will experience anaphylaxis during their lifetime.